All companies
Visit website
MICOY THERAPEUTICS
OperatingMicoy Therapeutics, Inc.
Healthcare · Biotech · Founded 2024
Developing therapeutics to block harmful autoantibodies
Post-money valuation ⓘ
$10.1M
As of Jan 2025 · from Micoy Therapeutics Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$0
Across 1 round since 2024
Latest share price
$1.75
Micoy Therapeutics Common Stock 1 offering price
Financials
FY2022–FY2023 · from SEC filings · hover any figure for its source$0
−$136K
2022
$0
−$1.5M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022
FY2023
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$136,210
-$1,451,848
Taxes paid
$0
$0
Balance sheet
Cash
$0
$0
Accounts receivable
$0
$0
Total assets
$0
$0
Short-term debt
$0
$0
Long-term debt
$0
$0
Total liabilities
$0
$0
Other
Headcount
—
4
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$10.1M
post-money
Micoy Therapeutics Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $1.2MPost-money $10.1M
Reg CF annual-report compliance
Delinquent
Filed 0 of 2 annual reports (FY2024–FY2025)
Missing: 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0002041723Share price $1.75
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.